PEAR THERAPEUTICS

Pear Therapeutics Announces Agreement with SoftBank Corp. to Develop a Digital Therapeutic for Sleep/Wake Disorders for the Japanese Market

Retrieved on: 
Monday, March 21, 2022
General Health, Health, Other Health, Therapy, NTN, Digital twin, PDT, 2009 Davis Cup, Investment, Marketing, Smartphone, Preventive healthcare, Somnolence, Insomnia, Atmospheric satellite, HAPS, Cognitive behavioral therapy for insomnia, Digitalization, Line Corporation, ESG, SoftBank Group, Accident, AI, Happiness, Patient, CEO, PEAR, Communication, Adult, Dow Jones, Quality of life, Association, Cognitive behavioral therapy, FTSE4Good Index, IOT, Sleep, Health care provider, Solution, FDA, Opioid use disorder, Telecommunication, Pharmaceutical industry, Hospital, Nasdaq, Pear, PEAR THERAPEUTICS, SOFTBANK CORP., PEAR THERAPEUTICS, SOFTBANK CORP.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with SoftBank Corp. (SoftBank) to develop a Japanese-language digital therapeutic for the treatment of sleep/wake disorders for the Japanese market.

Key Points: 
  • Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced an agreement with SoftBank Corp. (SoftBank) to develop a Japanese-language digital therapeutic for the treatment of sleep/wake disorders for the Japanese market.
  • In the United States, Pear is marketing Somryst, the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
  • Pursuant to the agreement, Pear will develop digital therapeutic applications for the treatment of sleep/wake disorders for the Japanese market and SoftBank will investigate the Japanese market potential for those applications, and SoftBank has an option to negotiate an exclusive license for Pears digital therapeutics for sleep/wake disorders in Japan.
  • The Japanese market has a large unmet need in treating people with sleep disorders, said Corey McCann, M.D., Ph.D., President and CEO of Pear.

Pear Therapeutics to Further Support Point32Health Members in Recovery from Substance Use Disorders

Retrieved on: 
Thursday, January 13, 2022
Health, General Health, Reset, PDT, Current Medical Research and Opinion, Patient, Journal of Medical Economics, Industry, Therapy, Technology, Policy, Safety, Publication, Mental health, Substance use disorder, Randomized controlled trial, COVID-19, MBA, DOI, Opioid use disorder, Harvard Pilgrim Health Care, Disease management, Reading, Heart, Doctor of Philosophy, Multimedia, Postgraduate Medicine, Insomnia, Treatment, Suicidal ideation, FDA, Smartphone, SUD, BA, Health, Buprenorphine, Tufts Health Plan, Cognitive behavioral therapy, Language isolate, Pharmacoeconomics, Hospital Practice, Substance abuse, Income, LICSW, Journal, Population, Digital, OUD, Pear, Policy by press release, MD, Risk, PEAR, Pharmaceutical industry, Medical device, Management, Birth control, Hospital, Nasdaq, Pear Therapeutics, Point32Health, PEAR THERAPEUTICS, POINT32HEALTH

We are delighted to again work with Pear Therapeutics to provide our members with high quality treatment options that will allow for tangible and measurable results.

Key Points: 
  • We are delighted to again work with Pear Therapeutics to provide our members with high quality treatment options that will allow for tangible and measurable results.
  • We are pleased to enter into this relationship with Point32Health to further support their members with access to innovative, FDA-authorized treatments for addiction without fear of stigma, said Julia Strandberg, Chief Commercial Officer at Pear Therapeutics.
  • Pear Therapeutics is a true collaborator, and we are excited to provide more of our members with access to this pioneering treatment option.
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).

Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders

Retrieved on: 
Wednesday, December 15, 2021
General Health, Health, Technology, Managed Care, Software, Therapy, OUD, Randomized controlled trial, Doctor of Philosophy, Population, Reset, SUD, Opioid use disorder, Journal, Risk, DOI, Patient, MBA, Insomnia, Treatment, Suds, Transformation, FDA, Safety, Substance abuse, Reading, Postgraduate Medicine, Health, MAT, PDT, BA, MD, Pharmacoeconomics, Digital, PEAR, Current Medical Research and Opinion, Suicidal ideation, Population Health Management, Good, Substance use disorder, Buprenorphine, Policy, Multimedia, Publication, View, Smartphone, Policy by press release, Cognitive behavioral therapy, Journal of Medical Economics, Hospital Practice, Language isolate, Technology, Pharmaceutical industry, Hospital, Birth control, Medical device, Pear, Nasdaq, Pear Therapeutics, Crossroads, PEAR THERAPEUTICS, CROSSROADS

Crossroads is extremely excited to continue our cooperation with Pear Therapeutics, says Tripp Wylie, Director of Transformation for Crossroads.

Key Points: 
  • Crossroads is extremely excited to continue our cooperation with Pear Therapeutics, says Tripp Wylie, Director of Transformation for Crossroads.
  • With access to patient-reported data, our clinicians can provide measurement-based care throughout a patients treatment journey to help improve outcomes.
  • Crossroads has been providing outpatient medication-assisted treatment (MAT) for more than 16 years to people suffering from OUD.
  • This expansion underscores the shared commitment by both Crossroads and Pear to provide access to innovative treatment options in our fight against the growing addiction crisis.

Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics

Retrieved on: 
Tuesday, June 22, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, SoftBank Group, Vodafone, Companies, Economy of Japan, Telecommunications, Thimble Point Acquisition Corp., Pear Therapeutics, THIMBLE POINT ACQUISITION CORP., PEAR THERAPEUTICS

Thimble Point sought to collaborate with a high-growth, tech-enabled company with the potential to disrupt large and established industries.

Key Points: 
  • Thimble Point sought to collaborate with a high-growth, tech-enabled company with the potential to disrupt large and established industries.
  • Our growth capital comes at an inflection point for Pear, as the team works towards expected near-term value creation milestones.
  • We believe prescription digital therapeutics are creating a new category of medicine with applications worldwide, said Kirthiga Reddy, Partner at SoftBank Investment Advisers.
  • Neither Thimble Point nor Pear gives any assurance that either Thimble Point or Pear will achieve its expectations.